Traumatic brain injury (TBI) is a leading cause of acquired neurologic disability in children. Erythropoietin (EPO), an anti-apoptotic cytokine, improved cognitive outcome in adult rats after TBI. To our knowledge, EPO has not been studied in a developmental TBI model. Hypothesis: We hypothesized that EPO would improve cognitive outcome and increase neuron fraction in the hippocampus in 17-day-old (P17) rat pups after controlled cortical impact (CCI). Methods: EPO or vehicle was given at 1, 24, and 48 h after CCI and at post injury day (PID) 7. Cognitive outcome at PID14 was assessed using Novel Object Recognition (NOR). Hippocampal EPO levels, caspase activity, and mRNA levels of the apoptosis factors Bcl2, Bax, Bcl-xL, and Bad were measured during the first 14 days after injury. Neuron fraction and caspase activation in CA1, CA3, and DG were studied at PID2. Results: EPO normalized recognition memory after CCI. EPO blunted the increased hippocampal caspase activity induced by CCI at PID1, but not at PID2. EPO increased neuron fraction in CA3 at PID2. Brain levels of exogenous EPO appeared low relative to endogenous. Timing of EPO administration was associated with temporal changes in hippocampal mRNA levels of EPO and pro-apoptotic factors. Conclusion/Speculation: EPO improved recognition memory, increased regional hippocampal neuron fraction, and decreased caspase activity in P17 rats after CCI. We speculate that EPO improved cognitive outcome in rat pups after CCI as a result of improved neuronal survival via inhibition of caspase-dependent apoptosis early after injury.
Get full access to this article
View all access options for this article.
References
1.
LangloisJA, Rutland-BrownW, and ThomasKE. (2005). The incidence of traumatic brain injury among children in the United States: Differences by race. J Head Trauma Rehabil, 20:229–238.
2.
LangloisJA, Rutland-BrownW, and WaldMM. (2006). The epidemiology and impact of traumatic brain injury: A brief overview. J Head Trauma Rehabil, 21:375–378.
3.
YeatesKO, TaylorHG, WadeSL, DrotarD, StancinT, and MinichN. (2002). A prospective study of short- and long-term neuropsychological outcomes after traumatic brain injury in children. Neuropsychology, 16:514–523.
4.
YeatesKO, ArmstrongK, JanuszJ, TaylorHG, WadeS, StancinT, and DrotarD. (2005). Long-term attention problems in children with traumatic brain injury. J Am Acad Child Adolesc Psychiatry, 44:574–584.
5.
CatroppaC, and AndersonV. (2007). Recovery in memory function, and its relationship to academic success, at 24 months following pediatric TBI. Child Neuropsychology, 13:240–261.
6.
AndersonV, GodfreyC, RosenfeldJV, and CatroppaC. (2012). 10 years outcome from childhood traumatic brain injury. Int J Dev Neurosci, 30:217–224.
7.
AndersonVA, CatroppaC, HaritouF, MorseS, and RosenfeldJV. (2005). Identifying factors contributing to child and family outcome 30 months after traumatic brain injury in children. J Neurol Neurosurg Psychiatry, 76:401–408.
8.
SlomineBS, McCarthyML, DingR, et al. (2006). Health care utilization and needs after pediatric traumatic brain injury. Pediatrics, 117:e663–674.
9.
AitkenME, McCarthyML, SlomineBS, et al. (2009). Family burden after traumatic brain injury in children. Pediatrics, 123:199–206.
10.
MammisA, McIntoshTK, and ManikerAH. (2009). Erythropoietin as a neuroprotective agent in traumatic brain injury Review. Surg Neurol, 71:527–531.
11.
DameC, JuulSE, and ChristensenRD. (2001). The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential. Biol Neonate, 79:228–235.
12.
YatsivI, GrigoriadisN, SimeonidouC, et al. (2005). Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J, 19:1701–1703.
13.
GrassoG, SfacteriaA, MeliF, FodaleV, BuemiM, and IacopinoDG. (2007). Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res, 1182:99–105.
14.
MahmoodA, LuD, QuC, et al. (2007). Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg, 107:392–397.
15.
ZhuL, WangHD, YuXG, et al. (2009). Erythropoietin prevents zinc accumulation and neuronal death after traumatic brain injury in rat hippocampus: In vitro and in vivo studies. Brain Res, 1289:96–105.
16.
PolsterBM, RobertsonCL, BucciCJ, SuzukiM, and FiskumG. (2003). Postnatal brain development and neural cell differentiation modulate mitochondrial Bax and BH3 peptide-induced cytochrome c release. Cell Death Differ, 10:365–370.
17.
RiceD, and BaroneSJr. (2000). Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ Health Perspect, 108:511–533.
18.
DigicayliogluM, BichetS, MartiHH, WengerRH, RivasLA, BauerC, and GassmannM. (1995). Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA, 92:3717–3720.
19.
JuulSE, YachnisAT, RojianiAM, and ChristensenRD. (1999). Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol, 2:148–158.
20.
NoguchiCT, AsavaritikraiP, TengR, and JiaY. (2007). Role of erythropoietin in the brain. Crit Rev Oncol Hematol, 64:159–171.
21.
SakanakaM, WenTC, MatsudaS, MasudaS, MorishitaE, NagaoM, and SasakiR. (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA, 95:4635–4640.
22.
SheinNA, GrigoriadisN, AlexandrovichAG, et al. (2008). Differential neuroprotective properties of endogenous and exogenous erythropoietin in a mouse model of traumatic brain injury. J Neurotrauma, 25:112–123.
23.
LiaoZB, ZhiXG, ShiQH, and HeZH. (2008). Recombinant human erythropoietin administration protects cortical neurons from traumatic brain injury in rats. Eur J Neurol, 15:140–149.
24.
LiaoZB, JiangGY, TangZH, et al. (2009). Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats. Neurol India, 57:722–728.
25.
XiongY, MahmoodA, QuC, et al. (2010). Erythropoietin improves histological and functional outcomes following traumatic brain injury in mice in the absence of the neural erythropoietin receptor. J Neurotrauma, 27:205–215.
26.
MaieseK, LiF, and ChongZZ. (2004). Erythropoietin in the brain: Can the promise to protect be fulfilled?. Trends Pharmacol Sci, 25:577–583.
27.
ChongZZ, KangJQ, and MaieseK. (2003). Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol, 138:1107–1118.
28.
PavlicaS, MilosevicJ, KellerM, et al. (2012). Erythropoietin enhances cell proliferation and survival of human fetal neuronal progenitors in normoxia. Brain Res, 1452:18–28.
29.
XenocostasA, CheungWK, FarrellF, et al. (2005). The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol, 61:189–195.
30.
JuulSE, McPhersonRJ, FarrellFX, JolliffeL, NessDJ, and GleasonCA. (2004). Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate, 85:138–144.
31.
SchoberME, BlockB, BeachyJC, StatlerKD, GizaCC, and LaneRH. (2010). Early and sustained increase in the expression of hippocampal IGF-1, but not EPO, in a developmental rodent model of traumatic brain injury. J Neurotrauma, 27:2011–2020.
32.
AntunesM, and BialaG. (2012). The novel object recognition memory: Neurobiology, test procedure, and its modifications. Cognit Process, 13:93–110.
33.
BittigauP, SifringerM, PohlD, et al. (1999). Apoptotic neurodegeneration following trauma is markedly enhanced in the immature brain. Ann Neurol, 45:724–735.
34.
PohlD, BittigauP, IshimaruMJ, et al. (1999). N-Methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. Proc Natl Acad Sci USA, 96:2508–2513.
35.
D'AmelioM, CavallucciV, and CecconiF. (2010). Neuronal caspase-3 signaling: Not only cell death. Cell Death Differ, 17:1104–1114.
36.
BrinesML, GhezziP, KeenanS, et al. (2000). Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA, 97:10526–10531.
37.
StatlerPA, McPhersonRJ, BauerLA, KellertBA, and JuulSE. (2007). Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res, 61:671–675.
38.
LieutaudT, AndrewsPJ, RhodesJK, and WilliamsonR. (2008). Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in rats. J Neurotrauma, 25:1179–1185.
39.
GonzalezFF, AbelR, AlmliCR, MuD, WendlandM, and FerrieroDM. (2009). Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Develop Neurosci, 31:403–411.
40.
RegerML, HovdaDA, and GizaCC. (2009). Ontogeny of rat recognition memory measured by the novel object recognition task. Develop Psychobiol, 51:672–678.
41.
PaxinosG, and CharlesW. (2005). The Rat Brain in Stereotaxic Coordinates.
42.
MarvizonJC, PerezOA, SongB, ChenW, BunnettNW. GradyEF, and ToddAJ. (2007). Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: Localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience, 148:250–265.
43.
PierceDR, HayarA, WilliamsDK, and LightKE. (2011). Olivary climbing fiber alterations in PN40 rat cerebellum following postnatal ethanol exposure. Brain Res, 1378:54–65.
44.
SwigartRH. (1965). Polycythemia and right ventricular hypertrophy. Circ Res, 17:30–38.
45.
RakusanK, CicuttiN, and KolarF. (2001). Cardiac function, microvascular structure, and capillary hematocrit in hearts of polycythemic rats. Am J Physiol Heart Circ Physiol, 281:H2425–2431.
46.
BroadbentNJ, GaskinS, SquireLR, and ClarkRE. (2010). Object recognition memory and the rodent hippocampus. Learn Mem, 17:5–11.
47.
ScottHL, TamagniniF, NarduzzoKE, et al. (2012). MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex. Eur J Neurosci, 36:2941–2948.
48.
McBrideJ, ZhaoX, NicholsT, et al. (2013). Scalp EEG-based discrimination of cognitive deficits after traumatic brain injury using event-related Tsallis entropy analysis. IEEE Trans Biomed Eng, 60:90–96.
49.
MandalisA, KinsellaG, OngB, and AndersonV. (2007). Working memory and new learning following pediatric traumatic brain injury. Dev Neuropsychol, 32:683–701.
50.
ScafidiS, RaczJ, HazeltonJ, McKennaMC, and FiskumG. (2010). Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain. Develop Neurosci, 32:480–487.
51.
LiYX, DingSJ, XiaoL, GuoW, and ZhanQ. (2008). Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull, 24:89–95.
52.
AgarwalMK, AgarwalML, AtharM, and GuptaS. (2004). Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. Cell Cycle, 3:205–211.
53.
AmmarHI, SabaS, AmmarRI, ElsayedLA, GhalyWB, and DhingraS. (2011). Erythropoietin protects against doxorubicin-induced heart failure. Am J Physiol Heart Circ Physiol, 301:H2413–2421.
54.
LowthertL, LeffertJ, LinA, et al. (2012). Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Biol Mood Anxiety Dis, 2:15.
55.
SrinivasanA, LiF, WongA, et al. (1998). Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J Biol Chem, 273:4523–4529.
56.
ChenG, ShiJX, HangCH, XieW, LiuJ, and LiuX. (2007). Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: A potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). Neurosci Lett, 425:177–182.
57.
DzietkoM, Felderhoff-MueserU, SifringerM, et al. (2004). Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis, 15:177–187.
58.
JuulSE, McPhersonRJ, BauerLA, LedbetterKJ, GleasonCA, and MayockDE. (2008). A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics, 122:383–391.
59.
WuYW, BauerLA, BallardRA, et al. (2012). Erythropoietin for neuroprotection in neonatal encephalopathy: Safety and pharmacokinetics. Pediatrics, 130:683–691.
60.
VerdonckO, LahrechH, FranconyG, et al. (2007). Erythropoietin protects from post-traumatic edema in the rat brain. J Cereb Blood Flow Metab, 27:1369–1376.
61.
XiongY, LuD, QuC, GoussevA, SchallertT, MahmoodA, and ChoppM. (2008). Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. J Neurosurg, 109:510–521.
62.
SolaA, WenTC, HamrickSE, and FerrieroDM. (2005). Potential for protection and repair following injury to the developing brain: A role for erythropoietin?. Pediatr Res, 57:110R–117R.
63.
KimSS, LeeKH, SungDK, et al. (2008). Erythropoietin attenuates brain injury, subventricular zone expansion, and sensorimotor deficits in hypoxic-ischemic neonatal rats. J Korean Med Sci, 23:484–491.
64.
BittigauP, SifringerM, Felderhoff-MueserU, and IkonomidouC. (2004). Apoptotic neurodegeneration in the context of traumatic injury to the developing brain. Exp Toxicol Pathol, 56:83–89.
65.
AndersonV, CatroppaC, MorseS, HaritouF, and RosenfeldJ. (2005). Functional plasticity or vulnerability after early brain injury?. Pediatrics, 116:1374–1382.
66.
HagemeyerN, BoretiusS, OttC, et al. (2012). Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med, 18:628–635.
67.
GonzalezFF, McQuillenP, MuD, ChangY, WendlandM, VexlerZ, and FerrieroDM. (2007). Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Developmental Neuroscience, 29:321–330.
68.
ZhangY, ChoppM, MahmoodA, MengY, QuC, and XiongY. (2012). Impact of inhibition of erythropoietin treatment-mediated neurogenesis in the dentate gyrus of the hippocampus on restoration of spatial learning after traumatic brain injury. Exp Neurol, 235:336–344.
69.
WangY, ZhangZG, RhodesK, et al. (2007). Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol, 151:1377–1384.
70.
LiY, OgleME, WallaceGC, LuZY, YuSP, and WeiL. (2008). Erythropoietin attenuates intracerebral hemorrhage by diminishing matrix metalloproteinases and maintaining blood-brain barrier integrity in mice. Acta Neurochir Suppl, 105:105–112.
71.
SarginD, HassounaI, SperlingS, SirenAL, and EhrenreichH. (2009). Uncoupling of neurodegeneration and gliosis in a murine model of juvenile cortical lesion. Glia, 57:693–702.
72.
TangZ, SunX, HuoG, XieY, ShiQ, ChenS, WangX, and LiaoZ. (2013). Protective effects of erythropoietin on astrocytic swelling after oxygen-glucose deprivation and reoxygenation: Mediation through AQP4 expression and MAPK pathway. Neuropharmacology, 67:8–15.
73.
YamadaM, BurkeC, ColditzP, JohnsonDW, and GobeGC. (2011). Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain. Journal of Pathology, 224:101–109.
74.
LiuJ, NarasimhanP, SongYS, NishiT, YuF, LeeYS, and ChanPH. (2006). Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress. Glia, 53:360–365.
75.
VairanoM, Dello RussoC, PozzoliG, et al. (2002). Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci, 16:584–592.
76.
PonceLL, NavarroJC, AhmedO, and RobertsonCS. (2012). Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology, 20:31–38.
